Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03092505 · ClinicalTrials.gov registry record
Herpesviruses Reactivation In Hiv-Infected Women Initiating ART (HERA)
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 190
- Enrollment target
NCT03092505 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 190 participants.
The verdict
NCT03092505 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 190 participants
- Enrollment target
Study Summary
Background: Herpes virus can cause sores on the body. It can cause flu-like symptoms like fever and muscle aches, and even a type of cancer. Many people with HIV also have infections with herpes virus. When these people start taking HIV medicines, their herpes virus symptoms can suddenly start or become worse. Researchers want to find out more about how often this happens and why. Objective: To study the effects of HIV treatment in women who may have herpes virus infections. Eligibility: Women age 18 years and older who have been diagnosed with HIV infection. Design: Participants will be screened with a physical exam, medical history, and blood and urine tests. Participants will have about 8 study visits. Each will take about 1-2 hours. Participants will return to the clinic 1-2 weeks after the screening visit to receive their antiretroviral (ART) medicine. They will get instructions for taking it. Participants will have 6 more study visits over 1 year. During study visits, participants will have blood and urine tests, vaginal fluid collected, and an oral swab. They may have an external genital exam. They will get their next supply of ART medicine. Some participants may have a chest x-ray. Participants may have leukapheresis. Blood will be removed through a needle in an arm. It will be run through a machine that separates out the white blood cells. The rest of the blood will be returned through a needle in the other arm. The total time participants will be in the study is about 1 year. ...
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2018-06-15 |
| Est. Completion | 2021-02-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03092505
The ClinicalTrials.gov registry entry for NCT03092505 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03092505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03092505 about?
NCT03092505 is a clinical study titled "Herpesviruses Reactivation In Hiv-Infected Women Initiating ART (HERA)". Background: Herpes virus can cause sores on the body. It can cause flu-like symptoms like fever and muscle aches, and even a type of cancer. Many people with HIV also have infections with herpes virus. When these people start taking HIV medicines, their herpes virus symptoms can suddenly start or b...
What is the current status of trial NCT03092505?
This trial is currently completed. The enrollment target is 190 participants. The study started on 2018-06-15. Estimated completion is 2021-02-04.
Who is sponsoring clinical trial NCT03092505?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.